Winslow Evans & Crocker’s Jazz Pharmaceuticals JAZZ Stock Holding History

Winslow Evans & Crocker’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-106	Closed	-$14K	–	1152
2019 Q3	$14K	Hold	106	–	–	﹤0.01%	716
2019 Q2	$16K	Hold	106	–	–	﹤0.01%	715
2019 Q1	$16K	Hold	106	–	–	﹤0.01%	718
2018 Q4	$14K	Hold	106	–	–	﹤0.01%	699
2018 Q3	$18K	Hold	106	–	–	0.01%	684
2018 Q2	$20K	Hold	106	–	–	0.01%	670
2018 Q1	$15.9K	Hold	106	–	–	0.01%	689
2017 Q4	$14.1K	Hold	106	–	–	﹤0.01%	735
2017 Q3	$15.4K	Buy	106 +1	+1%	+$151	0.01%	725
2017 Q2	$16.3K	Sell	105 -1	-0.9%	-$153	﹤0.01%	796
2017 Q1	$15.2K	Hold	106	–	–	﹤0.01%	796
2016 Q4	$11.4K	Hold	106	–	–	﹤0.01%	848
2016 Q3	$12.8K	Hold	106	–	–	﹤0.01%	844
2016 Q2	$14.8K	Buy	106 +1	+1%	+$147	﹤0.01%	782
2016 Q1	$13.7K	Sell	105 -1	-0.9%	-$124	﹤0.01%	801
2015 Q4	$14.8K	Hold	106	–	–	﹤0.01%	816
2015 Q3	$13.9K	Hold	106	–	–	﹤0.01%	815
2015 Q2	$18.5K	Hold	106	–	–	0.01%	782
2015 Q1	$18.1K	Hold	106	–	–	0.01%	752
2014 Q4	$17.2K	Hold	106	–	–	﹤0.01%	767
2014 Q3	$16.9K	Buy	106 +1	+1%	+$154	﹤0.01%	776
2014 Q2	$15.4K	Hold	105	–	–	0.01%	738
2014 Q1	$14.6K	Buy	+105	New	+$15.8K	0.01%	744

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Winslow Evans & Crocker's JAZZ Position: Q4 2019 in Review

Winslow Evans & Crocker sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2019, closing a stake of 106 shares — an estimated $14K sold.

Winslow Evans & Crocker first reported a position in JAZZ in Q1 2014 and held it in 23 quarters. The position peaked at $20K in Q2 2018. 446 funds tracked by Wall St. Rank hold JAZZ as of Q4 2019.

Winslow Evans & Crocker reported no remaining Jazz Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Winslow Evans & Crocker sold 106 Jazz Pharmaceuticals shares in Q4 2019, an estimated $14K.
Winslow Evans & Crocker first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 23 quarters.
Winslow Evans & Crocker's Jazz Pharmaceuticals position peaked at $20K in Q2 2018.
446 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2019.

Based on Winslow Evans & Crocker's 13F filing for Q4 2019, filed 14 Jan 2020.